Drug Type AAV based gene therapy |
Synonyms adeno-associated virus serotype rh.10 vector expressing bevacizumab (REGENXBIO) |
Target |
Action antagonists |
Mechanism VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dystrophy, Macular | Preclinical | United States | - |





